The ideal goal of hepatitis B treatment is to achieve a functional cure, and the persistent cccDNA in the liver is a barrier to functional cure. Currently, antiviral drugs represented by pegylated interferon-α and nucleos (t) ide analogues cannot eliminate cccDNA, which is difficult to achieve functional cure. With the deepening of the exploration of various mechanisms and drug targets, significant progress has been made in the research and development of several novel drugs targeting the hepatitis B virus's life cycle and immune system, offering hope for a functional cure. This article presents an overview of the new progress in clinical research on antiviral therapy for chronic hepatitis B based on the literature published in recent years and international conference materials.
乙型肝炎治疗的理想目标是实现功能性治愈,但肝内持续存在的共价闭合环状DNA（cccDNA）是HBV长期感染的关键因素，也是难以实现彻底治愈的原因。当前以聚乙二醇干扰素α和核苷（酸）类似物为代表的抗病毒药物均不能消除cccDNA，因此难以实现功能性治愈。随着对各种机制和药物靶点的探索不断深化，许多针对乙型肝炎病毒生命周期和免疫系统的新药研发取得显著进展，为乙型肝炎的功能性治愈带来了希望。现结合近年发表的文献和国际会议资料，概述慢性乙型肝炎抗病毒治疗新药临床研究的最新进展。.
Keywords: Antiviral therapy; Chronic hepatitis B; Clinical trial; Functional cure.